Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
variants) was not associated with small vessel stroke (odds ratio [OR], 1.02 [95% CI, 0.95-1.10]), magnetic resonance imaging-confirmed lacunar stroke (OR, 0.95, [95% CI, 0.81-1.11]), nonlobar intracerebral hemorrhage (OR, 1.04 [95% CI, 0.72-1.50]), or vascular dementia (OR, 1.09 [95% CI, 0.95-1.25]).
Why it matters
This genetic analysis found that downregulating interleukin-6 signaling was not associated with small vessel stroke, lacunar stroke, brain hemorrhage, vascular dementia, or small vessel disease markers. The authors conclude that targeting IL-6 signaling is unlikely to prevent this type of small vessel disease.
-
For these neurodegenerative dementias, we observed that the chronological age did not align with their biological age, which was determined based on hippocampal transcript levels (i.e., transcriptional age).
Why it matters
This transcriptomic study of hippocampus tissue found that chronological age did not match biological age in Parkinson's disease dementia, Down syndrome dementia, and Alzheimer's disease, and identified 45 common differentially expressed genes. It highlights shared mechanisms but tests no treatment or prevention.
-
Cognitive assessment and analysis of plasma biomarkers are lower-cost options for the early assessment of Alzheimer's disease (AD).
Why it matters
In cognitively unimpaired older adults, lower plasma p-tau231 was associated with better delayed recall of the first words on a word-list memory test. This suggests a low-cost memory task may help flag early Alzheimer's-related pathology, but it is an association study with no treatment tested.
-
41/100
The developmental origin of Alzheimer disease (AD) has been proposed but is arguably debated.
Why it matters
Using human brain organoids carrying familial Alzheimer's APP mutations, this study found fewer mature neurons, more cell senescence and more Aβ production, and treatment with thymosin beta 4 rescued these deficits; beneficial effects were also seen in 5xfAD model mice. This identifies Tβ4 as a potential neuroprotective factor for disease intervention, but the work is at the organoid and animal stage and has not been tested in patients.
-
Blood-based biomarkers hold significant promise for the early detection and diagnosis of Alzheimer’s disease (AD) and other dementias.
Why it matters
This study of 2,656 Hispanic/Latino adults found significant associations between acceleration in epigenetic clocks and higher plasma levels of neurofilament light chain and amyloid beta 40. It examines relationships between aging measures and blood biomarkers, which may aid early detection, but no treatment, cure, or prevention was tested.
-
Semantic dementia (SD) is a clinical subtype of frontotemporal dementia characterized by impaired word comprehension and semantic memory, and occurs nearly always sporadically.
Why it matters
This proteomic study of the temporal cortex in semantic dementia found a striking difference in the abundance of TDP-43 and ANXA11 and their interacting proteins between the temporal cortex and the dentate gyrus. This suggests the disease involves brain-region specific molecular changes rather than one uniform process.
-
• This analysis consists of 567 participants revealed that vitamin B12 deficiency, not folate or vitamin B1 deficiency was associated with hippocampal atrophy detected by MRI-VSRAD analysis. • Vitamin B12 deficiency was associated with hyperhomocysteinemia. • Clear correlations were observed between hippocampal atrophy and vitamin B12 value.
Why it matters
This cross-sectional study found that vitamin B12 deficiency, but not folate or vitamin B1 deficiency, was associated with hippocampal atrophy detected by MRI in a dementia cohort. It also observed clear correlations between hippocampal atrophy and vitamin B12 values, with vitamin B12 deficiency associated with hyperhomocysteinemia.
-
Autophagic markers beclin 1, LC3II and p62, and lysosome-related marker cathepsin B, all upregulated in AD astrocytes, were significantly reduced, while autophagic flux was rescued, by stabilizing 20 nm-MERCS.
Why it matters
In astrocytes from an Alzheimer's mouse model, stabilizing the contact between the endoplasmic reticulum and mitochondria at a 20 nm distance reduced markers of impaired protein degradation and restored autophagic flux. This is early cell-based work suggesting a possible strategy, not a treatment proven in people.
-
All participants had heterozygous c.1184A > G, p.Asp395Gly in VCP.
Why it matters
People with a specific VCP gene change who developed symptoms in their 30s to 50s showed frontotemporal dementia-like dysfunction, frontal neurodegeneration, and tau deposition with microvacuolization. Two presymptomatic carriers in their 20s showed no radiological changes, and the study expands the spectrum of early-onset frontotemporal lobar degeneration.
-
AMS-17 treatment improved cognitive function, enhanced blood-brain barrier (BBB) integrity, and promoted remyelination in VaD mice.
Why it matters
In mice with vascular dementia, the compound AMS-17 improved cognitive function and reduced markers of inflammation and neurodegeneration. These are early animal findings, and the authors state AMS-17 needs further development before it could be tested for treating vascular dementia in humans.
-
Alzheimer disease (AD) is the most common form of dementia affecting more than 6 million people in the United States.
Why it matters
In human tissue samples and APP transgenic mice, the antibody ABBV-916 bound to a specific form of amyloid beta, reduced dense plaques, decreased amyloid plaques after three months of weekly administration, and inhibited plaque growth. These results are from laboratory and animal work, and the authors describe ABBV-916 as a promising drug candidate rather than a proven treatment.
-
Emerging evidence indicates that globus pallidus (GP) function can be modulated by orexin-A in movement disorders, while its role in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) remains unclear.
Why it matters
In this study of 20 healthy controls, 25 patients with Alzheimer's disease, and 16 with dementia with Lewy bodies, patients with Alzheimer's disease had higher plasma orexin-A levels, while those with dementia with Lewy bodies had elevated amyloid-β levels. No significant mediation by amyloid-β was found in Alzheimer's disease or across all participants.
-
Vascular dementia (VaD) is the second most common cause of dementia.
Why it matters
Bioinformatic analysis and validation in animals and patient serum found that complement genes C1QA, C1QB, C1QC and C5AR1 were highly expressed in vascular dementia and showed good diagnostic power. These are candidate early diagnostic biomarkers, not a treatment, cure or prevention.
-
EMCIs and LMCIs, especially LMCIs, exhibited poorer performance in almost all global and multidimensional cognitive tests.
Why it matters
This study found altered oxysterols, gut metabolites, and m6A methylation in different stages of mild cognitive impairment, with some combinations distinguishing MCI subgroups from healthy controls. It is an exploratory analysis of associations and does not show that targeting these markers treats, cures, or prevents Alzheimer's disease.
-
DNA methylation is a critical epigenetic mechanism involved in numerous physiological processes.
Why it matters
This review compares Illumina and Oxford Nanopore sequencing for DNA methylation analysis in Alzheimer's disease and frontotemporal dementia, discussing strengths and limitations. It provides methodological insights for research but no direct treatment, cure, or prevention.
-
The results showed that T. chuii extracts could protect neuronal cells from neurotoxic damage, especially against L-glutamate and H2O2.
Why it matters
Extracts from the microalga Tetraselmis chuii protected neuronal cells from damage in the laboratory, and some of its compounds crossed cell models of the blood-brain barrier and intestine. This is early cell-based research and does not show benefit in people with Alzheimer's disease.
-
Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head impact (RHI) exposure.
Why it matters
Among 447 brain donors with repetitive head impact exposure, a specific structural haplotype in the MAPT region was linked to dementia and greater tau burden in brain areas affected in CTE. This identifies a possible genetic factor behind why some people with similar head impact exposure develop CTE, but it does not provide a treatment or cure.
-
41/100
Natural products (NPs) are considered to be the oldest medicine in human history and numerous NPs have been investigated to search for therapeutic agents in various diseases.
Why it matters
This review looks at recent research on natural products that may reduce neuroinflammation by acting on microglia in the brain. It identifies this as an area of ongoing study but does not show that any natural product treats or prevents Alzheimer's disease.
-
BackgroundAlzheimer's disease (AD) causes cognitive function disorder and has become the preeminent cause of dementia.
Why it matters
In a mouse model of Alzheimer's-like pathology, semaglutide reduced amyloid buildup and improved cognitive function, apparently by activating AMPK and suppressing the TLR4/NF-κB inflammatory pathway. These are animal results only, so it is not yet known whether semaglutide helps people with Alzheimer's disease.
-
MobileNet achieved the highest overall performance, with an accuracy of 99.44%.
Why it matters
This study is about using deep learning to classify the relationship between wisdom teeth and the mandibular canal before surgery, not about Alzheimer's disease, so it has no relevance to Alzheimer's treatment, cure or prevention. It reported high accuracy for the deep learning models tested.
-
The STUB1/CHIP holds promise as a potential biomarker for distinguishing between SCI subjects, AD, and FTD.
Why it matters
This study found that cerebrospinal fluid levels of STUB1/CHIP were significantly lower in Alzheimer's disease, non-AD mild cognitive impairment, and frontotemporal dementia compared to subjective cognitive impairment, and HSP90AA1 was higher in AD. It suggests STUB1/CHIP holds promise as a potential biomarker for distinguishing between these conditions, but no treatment or cure is offered.
-
Cerebrovascular disease is associated with an increased likelihood of developing dementia.
Why it matters
In this UK Biobank study, poorer cerebrovascular health was linked to slower processing speed, explained by the microstructure of anterior white matter, with the effect stronger with age. The findings describe how cerebrovascular risk factors relate to cognition and do not test whether modifying them prevents dementia.
-
The origins of many diseases can be traced to the dynamic interplay of genetic predispositions and environmental exposures post-birth.
Why it matters
This review discusses how physical exercise affects epigenetic modifications in skeletal muscle, brain and heart, and suggests exercise could be studied as a non-drug approach to disease prevention. It does not report any specific effect of exercise on Alzheimer's disease.
-
SGLT2i empagliflozin and dapagliflozin exhibited neuroprotective actions against human Aβ 1–42 -induced neurotoxicity.
Why it matters
In cell models, the diabetes drugs empagliflozin and dapagliflozin reduced amyloid-induced cell death, oxidative stress, inflammasome markers and tau pathology. These are laboratory findings, and the study also found that a transporter-blocking compound increased the drugs' entry into mouse brain, so effects in people remain unknown.
-
• The new CB 2 antagonist PGN36 is able to cross the Blood-Brain Barrier. • PGN36 treatment effectively alleviates TAU P301L -induced cognitive decline . • PGN36 is able to reduce TAU protein expression levels and restore synaptic plasticity. • PGN36 modulates TAU P301L -induced pyroptosis.
Why it matters
In a mouse model expressing human TAU P301L, treatment with the new CB2 receptor antagonist PGN36 alleviated cognitive decline, reduced TAU protein levels, restored synaptic plasticity and modulated pyroptosis. These findings are from an animal model of frontotemporal dementia and do not establish a treatment, cure or prevention for Alzheimer's disease.
From across this topic
10 of the 4,748 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Role of complement in neurodegeneration and neuroinflammation
- Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study
- Stable isotope labelling kinetics of neurofilament light
- History of falls in Parkinson disease is associated with reduced cholinergic activity
- Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation
- SORL1 as a Putative Candidate Gene for a Novel Recessive Form of Complicated Hereditary Spastic Paraplegia: Insights from a Deep Functional Study
- Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery
- Microglia Gone Awry: Linking Immunometabolism to Neurodegeneration
- Cholinergic degeneration and early cognitive signs in prodromal Lewy body dementia
- Analysis of the hippocampal proteome in ME7 prion disease reveals a predominant astrocytic signature and highlights the brain-restricted production of clusterin in chronic neurodegeneration